These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 15478206)
1. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Manyam BV; Dhanasekaran M; Hare TA Phytother Res; 2004 Sep; 18(9):706-12. PubMed ID: 15478206 [TBL] [Abstract][Full Text] [Related]
2. Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Manyam BV; Dhanasekaran M; Hare TA Phytother Res; 2004 Feb; 18(2):97-101. PubMed ID: 15022157 [TBL] [Abstract][Full Text] [Related]
3. Antiparkinson drug--Mucuna pruriens shows antioxidant and metal chelating activity. Dhanasekaran M; Tharakan B; Manyam BV Phytother Res; 2008 Jan; 22(1):6-11. PubMed ID: 18064727 [TBL] [Abstract][Full Text] [Related]
5. Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease. Shim JS; Kim HG; Ju MS; Choi JG; Jeong SY; Oh MS J Ethnopharmacol; 2009 Nov; 126(2):361-5. PubMed ID: 19703534 [TBL] [Abstract][Full Text] [Related]
6. Levodopa-Reduced Johnson SL; Park HY; DaSilva NA; Vattem DA; Ma H; Seeram NP Nutrients; 2018 Aug; 10(9):. PubMed ID: 30131460 [No Abstract] [Full Text] [Related]
7. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Fleming SM; Delville Y; Schallert T Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106 [TBL] [Abstract][Full Text] [Related]
8. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899 [TBL] [Abstract][Full Text] [Related]
9. Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment. Bilbao G; Ruiz-Ortega JA; Miguens N; Ulibarri I; Linazasoro G; Gómez-Urquijo S; Garibi J; Ugedo L Brain Res; 2006 Apr; 1084(1):175-84. PubMed ID: 16574080 [TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Jin F; Wu Q; Lu YF; Gong QH; Shi JS Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189 [TBL] [Abstract][Full Text] [Related]
11. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease. Kasture S; Pontis S; Pinna A; Schintu N; Spina L; Longoni R; Simola N; Ballero M; Morelli M Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease. Crotty S; Fitzgerald P; Tuohy E; Harris DM; Fisher A; Mandel A; Bolton AE; Sullivan AM; Nolan Y Eur J Neurosci; 2008 Jan; 27(2):294-300. PubMed ID: 18190522 [TBL] [Abstract][Full Text] [Related]
14. Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study. Cilia R; Laguna J; Cassani E; Cereda E; Raspini B; Barichella M; Pezzoli G Parkinsonism Relat Disord; 2018 Apr; 49():60-66. PubMed ID: 29352722 [TBL] [Abstract][Full Text] [Related]
15. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Paillé V; Henry V; Lescaudron L; Brachet P; Damier P Mov Disord; 2007 Mar; 22(4):533-9. PubMed ID: 17230470 [TBL] [Abstract][Full Text] [Related]
16. Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile. Cassani E; Cilia R; Laguna J; Barichella M; Contin M; Cereda E; Isaias IU; Sparvoli F; Akpalu A; Budu KO; Scarpa MT; Pezzoli G J Neurol Sci; 2016 Jun; 365():175-80. PubMed ID: 27206902 [TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease. Singh S; Ahmad R; Mathur D; Sagar RK; Krishana B Indian J Exp Biol; 2006 Sep; 44(9):699-704. PubMed ID: 16999024 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078 [TBL] [Abstract][Full Text] [Related]